Cash Flow Statement (Annual)

RPRX / Repros Therapeutics, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016
Net Cash Provided By Used In Operating Activities
  Net Income Loss -27,234 -4,768 -12,491 -18,167 -27,721 -32,535 -29,192 -17,273
  Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Depreciation And Amortization 72 87 115 145 257 43 24 5
    Share Based Compensation 1,284 609 2,283 2,785 3,158 3,784 3,742 1,928
    Fair Value Adjustment Of Warrants - - - - - - - -
    Increase Decrease In Prepaid Deferred Expense And Other Assets -1,215 150 -229 307 -216 -3 -103 -18
    Increase Decrease In Accounts Payable And Accrued Liabilities 1,854 -568 100 2,049 -358 -629 -6 -259
  Net Cash Provided By Used In Operating Activities -22,081 -4,952 -9,764 -13,495 -24,448 -29,334 -25,329 -15,581
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Property Plant And Equipment - 7 15 30 63 0 0 0
  Net Cash Provided By Used In Investing Activities -502 -371 -335 -608 -911 0 0 0
Net Cash Provided By Used In Financing Activities
  Proceeds From Issuance Of Common Stock And Warrants - - - - - - - -
  Proceeds From Warrant Exercises - - - - - - - -
  Net Cash Provided By Used In Financing Activities 4,999 6,394 11,707 33,750 76,954 147 102 2,876
Cash And Cash Equivalents Period Increase Decrease -17,584 1,071 1,608 19,647 51,595 -29,187 -25,227 -12,705
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - - - -
Noncash Investing And Financing Items
  Settlement Of Warrant Liability Due To Cashless Warrant Exercises - - - - - - - -

Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)

CUSIP: 76028H209